“Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis”, European Respiratory Review

The authors of the study titled “Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis” conducted a search on MEDLINE, Embase, the Cochrane Central Register of Controlled Trials and Clinicaltrials.gov, from inception to December 2021, which yielded 5.006 records, of which the full texts of 222 records were reviewed and 53 randomised […]

“Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis”, European Respiratory Review Read Post »

COVID-19 vaccine response in solid organ transplant recipients: results from ORCHESTRA cohort study

To date, several reports have underlined low rates of antibody response to mRNA COVID-19 vaccines in solid organ transplant (SOT) recipients. According to the authors of an article titled “Evaluation of the Kinetics of Antibody Response to COVID-19 Vaccine in Solid Organ Transplant Recipients: The Prospective Multicenter ORCHESTRA Cohort” (1) previous studies assessing the antibody

COVID-19 vaccine response in solid organ transplant recipients: results from ORCHESTRA cohort study Read Post »

“Prevalence of mental disorders and impact on quality of life in patients with pulmonary arteriaI hypertension”, Frontiers in Psychiatry

Three patient representatives (Ralf Schmiedel, Pisana Ferrari, Hans-Dieter Kulla) contributed to the study and article. The first two are patients having undergone lung transplant, Mr Kulla is the President of ph e.v., German PH association. The other authors are Karen M. Olsson, Tanja Meltendorf, Manuel J Richter, Jan Fuge, Jan Christopher Kamp, Da-Hee Park, Henning

“Prevalence of mental disorders and impact on quality of life in patients with pulmonary arteriaI hypertension”, Frontiers in Psychiatry Read Post »

“Sotatercept for the Treatment of Pulmonary Arterial Hypertension”, New England Journal of Medicine

Marc Humbert, M.D., Ph.D.,  Vallerie McLaughlin, M.D.,  J. Simon R. Gibbs, M.D.,  Mardi Gomberg-Maitland, M.D.,  Marius M. Hoeper, M.D.,  Ioana R. Preston, M.D.,  Rogerio Souza, M.D., Ph.D.,  Aaron Waxman, M.D., Ph.D.,  Pilar Escribano Subias, M.D., Ph.D.,  Jeremy Feldman, M.D.,  Gisela Meyer, M.D.,  David Montani, M.D., Ph.D.,  et al.,  “Sotatercept for the Treatment of Pulmonary Arterial

“Sotatercept for the Treatment of Pulmonary Arterial Hypertension”, New England Journal of Medicine Read Post »

An international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic, Orphanet Journal of Rare Diseases, May 2021

During the COVID-19 pandemic, many health care systems suspended their non-urgent activities. Pulmonary Hypertension patients were subjected to the same rules as other patients during the COVID-19 pandemic, with no prioritised care despite their rare and severe condition. A consortium composed of pulmonary hypertension patient associations and scientific societies was created to launch the PH-CARE-COVID survey,

An international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic, Orphanet Journal of Rare Diseases, May 2021 Read Post »

“Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience”, European Respiratory Review

A very interesting article about epoprostenol, the first ever therapy to be approved for the treatment of pulmonary arterial hypertension. The development of epoprostenol followed on from the discovery of endogenous prostacyclins in the vasculature by Sir Salvator Moncada et al. in the 1970s. Shortly after this, epoprostenol was synthesised and shown to have anti-platelet activity

“Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience”, European Respiratory Review Read Post »

“Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet?”, European Respiratory Review, December 1, 2014

An article titled “Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet?”, published in the European Respiratory Review, the authors say that improved care in pulmonary arterial hypertension has led to increased longevity for patients, with a paralleled evolution in the nature of their needs. There is more focus on

“Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet?”, European Respiratory Review, December 1, 2014 Read Post »

TRANSLATE »
Scroll to Top